Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving...
Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "the Debtor"), a biopharmaceutical company dedicated to the development of life-saving...
In connection with its ongoing chapter 11 case, Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the...
Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat...
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat ...
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the release of new data on the Omicron variant neutralizing antibody (nAb)...
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) ("Sorrento") today announced it has entered into a licensing agreement with Columbia University...
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and SmartPharm Therapeutics, Inc. ("SmartPharm") announced today the signing of a letter of...
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has completed a preclinical batch of the STI-4398 (COVIDTRAP) protein and is...
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that Scilex Pharmaceuticals Inc. ("Scilex"), a majority-owned subsidiary of...
Effective September 26, 2017, the Board of Directors (the "Board") of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) appointed each of Dorman Followwill...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the Cantor Global Healthcare Conference, taking...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the 19th Rodman and Renshaw global investment...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the transactions contemplated by the Contribution Agreement it entered with...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.